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y Farmacéuticas, Universidad de Chile, Santiago, Chile
f Institut de Neurociències, Universitat Barcelona, Barcelona, Spain
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Abstract. The most common type of dementia is Alzheimer’s disease (AD), a progressive neurodegenerative disease
characterized by impairment in cognitive performance in aged individuals. Currently, there is no effective pharmacological
treatment that cures the disease due to the lack of knowledge on the actual mechanisms involved in its pathogenesis. In the
last decades, the amyloidogenic hypothesis has been the most studied theory trying to explain the origin of AD, yet it does
not address all the concerns relating to its development. In the present study, a possible new preclinical treatment of AD
was evaluated using the ethyl acetate extract (EAE) of leaves of Ugni molinae Turcz. (synonym Myrtus ugni Molina Family
Myrtacea). The effects were assessed on female transgenic mice from a preclinical model of familial AD (APPswe/PS1dE9)
combined with a high fat diet. This preclinical model was selected due to the already available experimental and observational
data proving the relationship between obesity, gender, metabolic stress, and cognitive dysfunction; related to characteristics
of sporadic AD. According to chemical analyses, EAE would contain polyphenols such as tannins, flavonoid derivatives, and
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phenolic acids, as well as pentacyclic triterpenoids that exhibit neuroprotective, anti-inflammatory, and antioxidant effects.
In addition, the treatment evidenced its capacity to prevent deterioration of memory capacity and reduction of progression
speed of AD neuropathology.
Keywords: APPswe/PS1dE9, ethyl acetate extract, high fat diet, hippocampus, neuroinflammation, Ugni molinae
INTRODUCTION
Alzheimer’s disease (AD) is an irreversible,
chronic, and relentless neurodegenerative disease,
characterized by memory loss, psychoses, and affec-
tive disorders and behavioral alterations [1–5].
Multiple epidemiological studies have estimated that
the incidence of AD is expected to increase to 66
million diagnosed cases in the world by 2030 and
131 million by 2050. These values are the result of
increase in life expectancy and continuous aging of
developed societies. Nowadays, there are no cura-
tive therapies for AD [1, 3] and the drugs being
administered are only able to slow the progression
of the disease for a reduced period of time [1].
Also, they present variable effectiveness depending
on the individual characteristics of the patient and
their efficacy decreases as the disease progresses
[6–8].
The well-known neuropathological features
observed in AD brains include the presence of
extracellular amyloid- (A) plaques/deposits
intracellular neurofibrillary tangles (NFTs) and
synaptic dysfunction [9–14]. In addition, many
reports evidence a role of activated glia and its
pro-inflammatory mediators in the etiology of AD
[15–18]. Although the precise role of inflammatory
processes in AD pathophysiology is controversial,
it is believed that microglia and astrocytes become
activated, promoting the secretion of cytokines and
neurotoxic mediators, including tumor necrosis
factor alpha (TNF ), superoxide (O2– •), and nitric
oxide (NO), which exacerbate neuronal damage [15].
Thus, several authors have hypothesized that AD
could be described as a chronic brain inflammatory
disease [18]. Nonetheless, other elements have been
suggested as risk factors for the development of
late onset AD. Among them, the most considered
are age and vascular and metabolic disorders such
as hypertension, type II diabetes mellitus (T2DM),
dyslipidemia, and metabolic syndrome [19–23].
U. molinae is a native and wild shrub of the
Myrtaceae family. It grows in central-south Chile
(between the VII and X region), especially in the
Coast Mountains and in part of the pre-Andean
mountains. In Chilean folkloric medicine, the aerial
parts and its infusions have been used to treat urinary
infections, diabetes, inflammatory states and different
types of pain. Also, analgesic and anti-inflammatory
properties have been demonstrated by in vivo assays
using the extracts of U. molinae leaves [24–28]. In
these studies, it was determined that these effects are
due to the presence of phenolic compounds: genins
and heterosides of quercetin, kaempferol, myricetin,
epicatechin/catechin; gallic acid, quinic acid, tan-
nins and others similar compounds and pentacyclic
triterpenoids from ursane, oleanane and lupane cores
(Fig. 1A, B) [24–28].
Given the previous assumption on the important
role of inflammation in the development of AD-
like pathologies, in this study a familial model of
the disease was used to study the efficacy of the
extract from U. molinae as a novel disease-modifying
treatment. Likewise, since experimental preclinical
reported studies strongly suggest that obesity and
T2DM conditions might aggravate AD pathologies,




U. molinae leaves were collected and botani-
cally identified by Dr. Carla Delporte in April
2010, in south-central Chile (35◦45´S, 72◦33´W). A
voucher specimen was deposited in the herbarium
of the School of Chemical and Pharmaceutical Sci-
ences, University of Chile (SQF: 22462). Dried and
grinded leaves (2.0 kg) were successively treated for
extraction by maceration at room temperature with
hexane, dichloromethane, ethyl acetate, and ethanol
to obtain, after the concentration, the corresponding
dry extracts with a w/w yield of 1.4, 5.9, 3.7, and
22.2%, respectively. The selected ethyl acetate extract
(EAE) was dissolved in dimethyl sulfoxide and later
it was diluted in saline solution (NaCl 0.9% p/p) to
inject at a dosage of 30 mg/kg of mice.
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Fig. 1. Chemical structure of several compounds present in EAE of U. molinae leaves. A) Polyphenolic compounds. B) Pentacyclic triter-
penoids. C) Experimental design for this study. Female WT and APP/PS1 mice were used in this study. All animals were exposed to HFD
right after their weaning and, from the 4.5 months of age they were administered either the vehicle or EAE extract at 30 mg/kg daily. At 6
months of age all animals underwent the NORT and were sacrificed in order to obtain samples for IF assays.
Chemical characterization of EAE
Total phenolic content
The total phenolic content (TPC) was determined
by Folin Ciocalteau assay according to Peña-Cerda
et al. [25]. Briefly, EAE was dissolved in methanol:
water (2 : 8) and 30 L of sample was mixed with
30 L Folin Ciocalteau reagent (1 : 10 in water). Then
240 L of sodium carbonate (5% v/v) was added.
Finally, the detection was made at 40◦C in a 96-well
plate spectrophotometer (Multiskan GO, Thermo
Scientific, USA) and the absorbance was measured
at 765 nm after 20 min of reaction. A calibration
curve was made with gallic acid (y = 0.062x+0.053,
R2 = 0.998 and Fcalc = 0.30 < Ftab=3.71) as standard
compound. The TPC was expressed as mg gallic acid
per g dry extract.
Total flavonoid content
The total flavonoid content (TFC) was calcu-
lated by an AlCl3 complexation method according to
Peña-Cerda et al. [25]. Briefly, EAE was dissolved in
methanol and 30 L of sample was mixed with 10 L
of sodium acetate (1 M) and 240 L of distilled water.
The method was performed at room temperature in
a 96-well plate spectrophotometer under a 415 nm
wavelength, 30 min after the beginning of the reac-
tion. A calibration curve was made with quercetin as
standard compound (y = 0.049x + 0.003, R2 = 0.999
and Fcalc = 0.06 < Ftab = 3.49) and TFC was expressed
as mg quercetin per g dry extract.
Identification of phenolic compounds by mass
spectrometry
Methanolic solutions of EAE (5000 ppm) were
prepared and HPLC-UV-ESI-MS analyses were per-
formed to obtain the polyphenolic fingerprint of this
extract. The HPLC system was an Agilent 1100
(Agilent Technologies Inc., CA-USA) coupled with
an electrospray ion trap mass spectrometer Esquire
4000 ESI-IT (Bruker Daltonics GmBH, DE). Analy-
ses and UV detection were made at 270 and 360 nm
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correspondingly. HPLC separation was carried out
on a reverse phase Purospher® STAR RP-18 col-
umn (endcapped 5 m, Hibar® RT 250–4; Merck,
Darmstadt, Germany). Methanolic solution of EAE
was separated by HPLC gradient elution which was
established by mixing two mobile phases: phase A
(H2O/HCOOH 98 : 2) and phase B (H2O/CH3CN
/HCOOH 18 : 80 : 2), according to methodology used
by Michodjehoun-Mestres et al. [35]. The elution’s
run time was 90 min and the gradient elution was:
0–8 min 90% A, 8–45 min 84% A, 45–55 min 65%A,
55–72 min 20% A, 72–75 min 0% A, 75–78 min 95%
A, 80–90 min 90% A at a flow rate of 0.2 mL/min. The
ionization (nebulization) was performed by an elec-
trospray ionizator and an ion trap was used as mass
analyzer. Negative polarity was employed in ESI.
The following parameters were considered for mass
spectrometry: spray ionization voltage was 4000 V;
nitrogen (N2) was used as nebulizer gas; temperature
was 365◦C; pressure 45 psi; and flow rate 10 L/min.
Data was analyzed using Data Analysis Version 3.2
software (Bruker Daltonik GmbH, Germany). Com-
pound identification was done using Mass Bank
database or by comparison with scientific literature.
Animals
Female APPswe/PS1dE9 (APP/PS1) and
C57BL/6J wild-type (WT) mice were used
in this study. APP/PS1 animals co-express a
Swedish (K594M/N595 L) mutation of a chimeric
mouse/human amyloid precursor protein (APP),
together with the human exon-9-deleted variant of
presenilin 1 (PS1). Both mutations are associated
with AD and represent a preclinical model to
study some of the features of familial AD. The
animals were originally purchased from Jackson Lab
(https://www.jax.org/strain/004462). The original
background is (C57BL/6 x C3 H)-F2. Thus, living
colony in our facilities are currently maintained
as hemizygote against C57BL/6J for at least 8
generations.
The mice were fed for 6 months with either con-
trol (CT) or HFD (D08061110; Research Diets Inc.,
New Brunswick, USA). This diet is enriched with
hydrogenated coconut oil, increasing fat content up
to 45% (Table 1). Mice body weight was recorded
weekly from the beginning of treatment (4.5 months
old) until their sacrifice at 6 months of age. Animals
that underwent the treatment with EAE were injected
intraperitoneally (i.p.) daily from the 4.5 months of
age until their sacrifice at 6 months of age. These
Table 1




Fats (coconut oil) 45.0
Total 100.0
time periods were chosen in order to present the treat-
ment as a prevention and possible reversal method
of the negative neuropathophysiology of AD. EAE
was administered at a dosage of 30 mg/kg given the
maximum possible dissolution rate between dimethyl
sulfoxide and saline solution. The control mice
were injected with analogue proportions of dimethyl
sulfoxide diluted with saline solution.
Twenty-five animals were used in total, divided
into four groups: WT+HFD, APP/PS1 + HFD,
WT+HFD+EAE, and APP/PS1 + HFD+EAE.
Groups WT+HFD and APP/PS1 + HFD were
administrated with the vehicle where EAE was
dissolved. The experimental design is represented
in Fig. 1. All the animals were kept under con-
trolled temperature, humidity, and 12 h light/dark
conditions with food and water provided ad libitum.
In all situations, mice were treated in accordance
with the European Community Council Directive
86/609/EEC and the procedures established by the
Department d’Agricultura, Ramaderia i Pesca of the
Generalitat de Catalunya. Every effort was made to
minimize animal suffering and to reduce the number
of animals used. Following in vivo testing, the
animals were sacrificed and all mice were used for
immunohistochemistry (IHC) microscopy analysis.
Glucose Tolerance Test (GTT) - Insulin
Tolerance Test (ITT)
Before starting the treatment with EAE, the ani-
mals underwent a GTT and ITT test to determine
whether their metabolic state has acquired a diabeto-
genic/obesogenic profile. Animals were fasted for 6 h
previous to the intraperitoneal (i.p.) administration of
either substance. In GTT mice were injected a glucose
dosage of 1 g/kg, whereas in ITT, insulin was admin-
istered at a dosage of 0.75 ui/kg ratio. Next, blood
samples were analyzed from the tail vein in consec-
utive time periods. For GTT samples were extracted
at 5, 15, 30, 60, 120, and 180 min after the admin-
istration; in ITT measurements were made 15, 30,
45, 60,and 90 min after. Animals were continuously
observed and monitored and, in those cases in which
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glucose dropped under a concentration of 20 mg/dL,
animals were administered a glucose dosage of 1 g/kg
and kept under observation until glucose blood levels
stabilized and normal behavior was observed.
Novel Object Recognition Test (NORT)
The Novel Object Recognition Test was used to
evaluate hippocampal-dependent recognition mem-
ory of mice [35]. The task procedure consisted of
three phases: habituation, familiarization and probe.
In the habituation phase, mice explored individu-
ally a circular open-field arena of 40 cm of diameter
for three consecutive days, 10 min for each session.
On the fourth day (familiarization), each mouse was
placed in the arena containing two identical objects
(A + A) in the middle of the field for 10 min. To per-
form the test phase, mice were returned 24 h later
to the open-field with two objects, one was identical
to the day before and the other was a novel object
(A + B) for 10 min. Light intensity was kept constant
in all phases and the arena and objects were cleaned
with 96◦ ethanol between each animal to elimi-
nate olfactory cues. Exploration activity was defined
as the orientation of snout of the animals toward
the object, sniffing or touching. The exploratory
analysis was expressed as discrimination index
(DI). DI=(novel object exploration time/total explo-
ration time) – (familial object exploration time/total
exploration time), measured in seconds.
Immunohistochemistry
Mice used for IHC studies were anesthetized by
i.p. injection of sodium pentobarbital (80 mg/kg)
and intracardiacally perfused with 4% paraformalde-
hyde (PFA) diluted in 0.1 M phosphate buffer
(PB). Brains were removed and stored in the same
solution overnight (O/N) at 4
◦
C and then, they
were cryoprotected in 30% sucrose-PFA-PB solution.
Samples were frozen at –80
◦
C and coronal sections
of 20 m of thickness were obtained by a cryostat
(Leica Microsystems, Wetzlar, Germany) and kept in
cryoprotectant at –20◦C until use.
Free-floating sections were first washed three times
with 0.1 mol/L PBS pH 7.35 and, after, five times
with PBS-T (PBS 0.1 M, 0.2% Triton X-100). Then,
they were incubated in a blocking solution contain-
ing 10% fetal bovine serum (FBS), 1% Triton X-100
and PBS 0.1 M- 0.2% gelatin for 2 h at room tem-
perature. After that, slices were washed with PBS-T
(PBS 0.1 M, 0.5% Triton X-100) five times for 5 min
each and incubated with polyclonal rabbit anti-Glial
Fibrillary Acidic Protein (GFAP; 1 : 2000; Dako,
Glostrup, Denmark), rabbit anti-Ionized calcium-
binding adapter molecule (IBA1; 1 : 1000; Wako
Chemical USA), and mouse anti-A1–42 (12F4;
1 : 1250; Covance, USA) primary antibodies at 4◦C
O/N. Sequentially, sections were washed with PBS-T
(PBS 0.1 M, 0.5% Triton X-100) 5 times for 5 min
and incubated with Alexa Fluor 594 goat anti-rabbit
and Alexa Fluor 488 donkey anti-rabbit secondary
antibodies (1 : 500; Invitrogen, Eugene, OR, USA)
for 2 h at room temperature in the dark.
The staining for plaques was performed using
Thioflavin S (ThS 0.002%, Sigma-Aldrich) in a
0.033% dilution rate. Slices were incubated for 8 min
in the dark, washed with ethanol 50% twice for 1 min
and rinsed with PBS 0.1 M. Later, sections were
co-stained with 0.1 g/mL Hoechst 33258 (Sigma-
Aldrich, St Louis, MO, USA) for 15 min in the
dark, and washed with PBS 0.1M. Finally, the slices
were mounted using Fluoromount G (EMS) and the
image acquisition was performed with an epifluo-
rescence microscope (BX41 Laboratory Microscope,
Melville, NY-Olympus America Inc.).
Image analysis and quantification
We analyzed the cortex in brain coronal sections
obtained from Bregma –1.28 to –2.12 mm, in accor-
dance with the Paxinos and Franklin atlas [36]. The
analysis and quantification of IHCs and ThS stain-
ing were performed using images obtained with the
20x objective. 4–8 sections/animal from 4–6 ani-
mals/group were used in all quantifications, except
for particle analysis (3 animals/group).
Evaluation of astrocyte and microglia reaction
The quantification of astrocyte and microglia
reaction was performed with GFAP and IBA1 mark-
ers. The immmunopositive reactivity of the tissue
were done through the percentage area occupied by
Table 2
Content of pentacyclic triterpenoid in EAE (30 mg/Kg)
Pentacyclic triterpenoid %w/w
Madecassic acid 0.33 ± 0.09
Asiatic acid 2.43 ± 0.09
Alphitolic acid 2.82 ± 0.09
Corosolic acid 8.28 ± 0.21
Maslinic acid 2.25 ± 0.12
Betulinic acid 0.54 ± 0.21
Oleanolic/ursolic acid 6.27 ± 0.06
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fluorescent signal as previously described by de
Lemos et al. [37]. Briefly, images were captured and
calibrated using a scale. Then, were transformed to 8-
bits gray, inverted and highlighted the area occupied
by fluorescent signal (IBA1 or GFAP cells) under
fixed threshold using the NIH ImageJ software.
Evaluation of cortical Aβ load
To evaluate the number of A plaques and their
size (m2) Cell counter and particle quantification
Image J functions were used. A1–42 density of
aggregates were evaluated using both fluorescent IHC
(12F4) and ThS staining. Intensity was determined
as follows: Area of fluorescent signal (m2) / Total
analyzed area. It was expressed as % area.
Gliosis surrounding amyloid plaque
To quantify the astrocytes surrounding A plaques,
different plaques per tissue section using superim-
posed grid of 200×200 m2 were used. A plaques
were put in the center of the grid and then channels
were spliced using Image J. The size of GFAP positive
cells was determined using particle quantification of
Image J. Particles with GFAP immunoreaction minor
than 5 m2 were considered artefacts and therefore
were excluded from the analysis. In order to iden-
tify if there was gliosis around the plaques the ratio
between GFAP area surrounding the plaque and the
area of this plaque was calculated.
Microglial reactivity was evaluated by analyzing
microglial areas around A1–42 aggregates. To do
that, double IHC against IBA1 and A1–42 peptides
(12F4) were used. From cortical sections, the area
Table 3
EAE (270 nm). Identification of phenolic compounds by HPLC-UV-ESI-MS2 (ESI-IT)
Compound Tr (min) MW (g/MOL) [M-H] – (m/z) MS2 (m/z) Reference
1. Stricnin/isostricnin isomer (galloyl-HHDP-hexose) 3.7 634 633 300 274 420 a
2. Pedunculagin I/casuariin isomer (bis-HHDP-hexose) 3.7 784 783 300 481 a
3. Digalloyl glucose isomer (digalloyl hexose) 3.7 484 483 331 169 a
4. Gallic acid 4.0 170 169 125 b
5. Stricnin/isostricnin isomer (galloyl-HHDP-hexose) 6.4 634 633 300 274 420 a
6. Digalloyl glucose isomer (digalloyl hexose) 7.0 484 483 331 169 a
7. Pedunculagin I/casuariin isomer (bis-HHDP-hexose) 10.1 784 783 481 301 a
8. Digalloylquinic acid 10.5 496 495 343 325 169 a
9. Pedunculagin I/casuariin isomer (bis-HHDP-hexose) 11.4 784 783 481 300 a
10. Digalloyl glucose isomer (digalloyl hexose) 11.4 484 483 331 169 a
11. Pedunculagin I/casuariin isomer (bis-HHDP-hexose) 11.4 784 783 300 481 a
12. Digalloyl glucose isomer (digalloyl hexose) 12.8 484 483 331 169 a
13. Digalloyl glucose isomer (digalloyl hexose) 14.3 484 483 331 169 a
14. Digalloyl glucose isomer (digalloyl hexose) 16.0 484 483 169 331 a
15. Epicatechin/catechin 15.6 290 289 244 204 178 b
16. Trigalloyl hexose isomer 17.0 636 635 464 482 313 a
17. Myricetin galloyl hexoside 18.3 632 631 478 316 a
18. Trigalloylquinic acid 18.1 648 647 476 325 a
19. Flavogalonic dilactone acid isomer 18.7 470 468 450 425 300 a
20. Flavogalonic dilactone acid isomer 20.2 470 468 425 300 450 a
21. Myricetin galloyl hexoside 20.4 632 631 479 316 a
22. Digalloyl pentose 20.6 454 453 313 168 326 a
23. Myricetin galloyl hexoside 23.9 632 631 479 316 a
24. Myricetin deoxihexoside 26.7 464 463 317 463 a
25. Myricetin hexoside 28.0 480 479 316 179 271 b
26. Myricetin deoxihexoside 28.5 464 463 463 317 179 a
27. Quercetin galloyl hexoside (galloylquercetin) 31.6 616 615 463 301 a
28. Quercetin pentoside 33.0 433 433 301 150 a
29. Myricetin pentoside 34.3 450 449 318 179 152 b
30. Ellagic acid 35.5 302 301 300 228 185 a
31. Ellagic acid 36.2 302 301 300 228 185 a
32. Kaempferol galloyl hexoside 38.4 600 599 447 312 284 a
33. Quercetin pentoside 45.0 434 433 300 179 a
34. Quercetin deoxihexoside 48.8 448 447 447 301 a
35. Myricetin galloyl deoxihexoside 55.6 616 615 616 316 462 a
36. Quercetin 63.7 302 301 178 150 300 b
a, scientific article; b, database; Tr, retention time; MW, molecular weight; EAE, ethyl acetate extract.
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Table 4
EAE (360 nm). Identification of phenolic compounds by HPLC-UV-ESI-MS2 (ESI-IT)
Compound Tr (min) MW (g/mol) [M-H] – (m/z) MS2 (m/z) Reference
1. Digalloyl hexose isomer 14.4 484 483 313 331 169 a
2. Epicatechin/catechin 15.6 290 289 205 245 137 a, b
3. Digalloyl pentose 15.6 454 453 313 169 a
4. Trigalloylquinic acid 17.7 648 647 495 477 a
5. Trigalloyl hexose isomer 17.9 636 635 465 483 423 a
6. Trigalloylquinic acid 18.6 648 647 495 477 a
7. Trigalloyl hexose isomer 19.2 636 635 465 483 423 a
8. Flavogalonic dilactone acid isomer 20.1 470 468 425 450 a
9. Digalloyl pentose 20.5 454 453 313 169 a
10. Myricetin galloyl hexoside 23.5 632 631 479 316 a
11. Quercetin galloyl hexoside 31.5 616 615 615 463 301 a
12. Quercetin galloyl hexoside 33.2 616 615 615 463 301 a
13. Ellagic acid 35.3 302 301 301 229 185 a
14. Ellagic acid 36.2 302 301 301 229 185 a
15. Kaempferol galloyl hexoside 38.2 600 599 447 285 313 a
16. Quercetin pentoside 44.7 434 433 300 179 150 b
17. Quercetin pentoside 45.7 434 433 300 179 150 b
18. Quercetin hexoside 48.6 448 447 300 179 284 271 a
19. Myricetin galloyl deoxihexoside 53.8 616 615 615 316 463 a
20. Myricetin 53.6 318 317 178 150 b
21. Myricetin galloyl deoxihexoside 55.4 616 615 615 463 317 a
22. Myricetin galloyl deoxihexoside 55.8 616 615 615 316 463 a
23. Quercetin 63.6 302 301 178 150 301 b
a, scientific article; b, database; Tr, retention time; MW, molecular weight; EAE, ethyl acetate extract.
Fig. 2. Peripheral metabolic parameters in HFD-fed WT and APP/PS1 mice. Weekly bodyweight variation (A), GTT (B), and ITT (C) in
6-month-old mice (n = 5–12 independent samples per group). For the ITT and the GTT, AUC data were calculated from the time point 0 till
the end of the experiment. The results were presented as MEAN ± SEM. Statistical analysis was performed by two-way ANOVA test, with
Tukey´s post hoc test where ∗p < 0.05 and ∗∗p < 0.01.
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occupied by the fluorescent signal from their corre-
spondent channel (green = IBA1; red = A1–42) and
the ratio of IBA1/A1–42 were calculated.
Data analysis
All data is presented as mean alone or
mean ± SEM. Level of significance was fixed
at =0.05. Thus, calculated p-values<0.05 were
considered significant. Differences between sam-
ples/animals were evaluated using either two-way
ANOVA with Tukey’s and unpaired Student-t as
required. Both statistical analyses and graphs pre-
sented here were created with the Graph Pad InStat
software V5.0 (Graph Pad Software Inc., San Diego,
CA, USA).
RESULTS
Chemical characterization of EAE
EAE is composed of pentacyclic triterpenoids.
They were quantified according to Goity et al.
[28] (Table 2): corosolic and oleanolic/ursolic
mixtures (8.28 ± 0.21% and 6.27 ± 0.06, respec-
tively) were the most abundant triterpenoids in this
extract. Also, the polyphenolic content of EAE
was 75.05 ± 5.73 mg gallic acid equivalents/g dry
extract (2.25 ± 0.17 mg gallic acid equivalents/g
dry extract in the administrated dose, 30 mg/Kg).
Additionally, the flavonoid content of EAE was
27.7 ± 5.3 mg quercetin equivalents/g dry extract.
Moreover, additional polyphenolic derivatives using
mass spectrometry were identified: tannins as
gallotannins (di- and tri-galloyl derivatives), ellagi-
tannins (hexahydroxydiphenoyl (HHDP) and hexose
derivatives), and quinic acid derivatives. Also,
flavonoids as myricetin, quercetin, kaempferol, epi-
catechin/catechin, its heterosides, and phenolic acids
as gallic and caffeic acids derivatives were identified
(Tables 3 and 4).
Treatment with EAE avoids weight gain due to
HFD and improves cognitive function in
APP/PS1 + HFD mice.
Our data showed that EAE treatment decreases
body weight significantly in both genotypes, WT and
APP/PS1 (F (1, 34)=17.48; p = 0.0002) (Fig. 2). As
expected, HFD intake induced significant increases
in glucose plasma levels in the GTT and ITT tests,
Fig. 3. Graphical representation on the results of the NORT.
The results exemplify the beneficial effects of EAE on the
WT+HFD+EAE and APP/PS1 + HFD+EAE experimental groups.
Values were calculated according to the following formula:
Discrimination ratio = (Time spent exploring the new object –
Time spent exploring the known object)/Total exploration time.
Results were represented as MEAN ± SEM. Statistical analysis
was obtained from a two-way ANOVA test followed by a Tuckey’s
post-hoc (∗p < 0.05 and ∗∗p < 0.01).
Table 5
Time of exploration (seconds) recorded in these study
A B A B
object object object object
WT HFD 3.09 3.54 APP/PS1 + HFD 9.50 4.80
2.23 1.85 1.87 2.19
3.09 3.71 6.00 3.00
6.83 5.64 39.20 33.50
0.71 0.76 2.19 2.07
1.10 0.651 WT+HFD+EAE 6.34 7.26
5.53 4956 5.25 4.81
8.30 8.60 3.22 7.20
17.30 26.90 0.12 9.50
0.60 1.00 3.05 7.64
1.00 1.60 APP/PS1 + HFD+EAE 1.37 3.8
1.80 1.50 4.68 6.59
1.90 1.3 3.32 5.80
1.60 6.40 5.34 6.08
0.80 0.30 11.34 13.07
2.60 3.60 3.54 5.45
0.70 0.40
analyzed by two-way ANOVA (F(1, 42)=17.81;
p = 0.001, F(1, 24)=23.49; p < 0.0001), respectively.
Furthermore, EAE treatment significantly
improved cognitive performance when evaluat-
ing using the behavioral NORT (F (1, 34)=17,
48; p = 0.002) (Fig. 3). It can be observed that
in APP/PS1 + HFD transgenic mice that there
was a significantly reduction versus WT+HFD
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Fig. 4. Fluorescent IHC against GFAP (A, a, B, b, C and c) and IBA1 (E, e, F, f, G and g) in the cortex of the mice untreated and treated
with EAE. Low astrocytic reactivity in WT+HFD (A, a) and WT+HFD+EAE (B, b) mice (* indicate astrocytes). As is observed in E there
is a microglial reactivity in WT+HFD (*, E, e) and a softly reduction of the reactivity due to EAE in WT+HFD+EAE (*, F, f). Meanwhile,
transgenic APP/PS1 + HFD mice show a reactive morphology of astrocytes (arrowheads, C, c) and microglia (arrowheads. G, g) surrounding
plaques. A reduction in astrocyte (D, c) and microglial (F, f) reactivity is observed in the APP/PS1 + HFD mice treated with EAE (arrowheads).
Quantification of GFAP (J) and IBA1 (K) positive cells is shown in the graph bars. Graphs represent the mean ± SEM. (∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001) Abbreviations: CTx, cortex; CA1, cornu ammonis; DG, dentate gyrus. Scale bar for A. B. C. D, E, F, G, and H = 400 m. Scale
bar for a, b, c, d, e, f, g, and h = 100 m. Statistical analysis was performed with the two-way ANOVA, with a Tukey’s post hoc test.
mice (p < 0.01). In addition, WT+HFD+EAE and
APP/PS1 + HFD+EAE mice improved their DI
when comparing them with their corresponding
untreated groups (WT+HFD and APP/PS1 + HFD)
(p < 0.05; p < 0.05). Time of exploration is reported
in Table 5.
Reduction in cellular glial reactivity in the brain
of APP/PS1 + HFD mice treated with EAE
To evaluate the effects of EAE on the modula-
tion of inflammatory responses, specifically, astroglia
and microglial reactivity, different brain areas of
WT and APP/PS1 mice fed with HFD and treated
with EAE were analyzed through IHC assays. The
detection for GFAP, the intermediate filament system
of adult astrocytes, which is used as an astroglio-
sis marker, revealed a noticeable increase in the
percentage of reactive tissue area in the cortex of
APP/PS1 + HFD (Fig. 4 C, c) of 14.5% versus 4.5 %
of WT+HFD mice (p < 0.001, Fig. 4 in Graph I) and a
reduction of astrogliosis of 14.5% in APP/PS1 + HFD
(Fig. 4 C, c) versus 7.5% APP/PS1 + HFD+EAE
(Fig. 4D, d, p < 0.01, Fig. 4 in Graph I). Two-
way ANOVA, genotype and treatment with EAE
as factor: F(1, 12)=22,46, p = 0.0005 for genotype;
F(1, 12)=6,753, p = 0.02 for treatment with EAE;
Interaction F(1,12)=5,820, p = 0.0328.
Meanwhile, IHC against IBA1, a protein upreg-
ulated in activated microglia, revealed an increase
in APP/PS1 + HFD of 17.5% (Fig. 4 G, g) in com-
parison to WT+HFD with 13.6 % (Fig. 3E, e)
essentially in cortical areas (p < 0.05, Fig. 4K). In
both genotypes fed with HFD (WT and APP/PS1),
the treatment with EAE induced a reduction on
microglial reactivity: 9.2% (WT+HFD+EAE) ver-
sus 13.3% (WT+HFD) (p < 0.05, Fig. 4F, f versus
4E, e) and 12.4% (APP+HFD+EAE versus 17%
APP+HFD+EAE) (p < 0.05, Fig. 4 H, h versus 4 G,
g). Two-way ANOVA, genotype and treatment with
EAE as factor: F(1, 12)=22,46, p = 0.0005 for geno-
type; F(1, 12)=6,753, p = 0.02 for treatment with
EAE; Interaction F(1,12)=5,820, p = 0.0328.
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Fig. 5. Staining of A plaques by ThS in the cortex and hippocampus. It was performed in APP/PS1+HFD and APP/PS1+HFD+EAE (A, B)
and APP+HFD+EAE groups (B, C) and allowed the visualization of cored A plaques (arrowhead; a and b). The analysis of the effect of
EAE on A plaques revealed that the number of the plaques were reduced in APP/PS1 + HFD treated with EAE mice as is observed in
cortex (A, a versus C, c; Graph in E, ∗p < 0.05). Also, evaluation of size plaque area (Graph in F,∗p < 0.05) and ThS-positive plaque density
(Graph in G,∗p < 0.05) showed how EAE treatment reduces A load. Graphs E and G represent the mean ± SEM Graph F represent mean
with individual quantification values of n = 3/group. The statistical analysis was determined from Student t-test. Abbreviations: CTX, cortex;
CA1, cornu ammonis 1; CA3, cornu ammonis 3; DG, Dentate gyrus. Scale bar for A, B, C and D = 400 m, Scale bar a, b, c and d = 100 m.
Attenuation of Aβ pathology in the APP/PS1
mouse brain treated with EAE
The ThS stain revealed A deposits in cerebral
cortex and hippocampus of APP/PS1 + HFD mice
(Fig. 5A). The number of these deposits was reduced
from an average of 67 plaques (APP+HFD) ver-
sus 37 plaques (Fig. 5E) (p < 0.05, Fig. 5E) and
furthermore there is a reduction in the plaque size
from a mean of 550 m2 (APP/PS1 + HFD) to
228 m2 (APP/PS1 + HFD+EAE) (p < 0.05, Fig. 5F).
This effectiveness was confirmed by measuring A in
ThS staining and IHC against A1–42 peptide load as
the percentage of the area of plaques versus total area.
We observed that there was a reduction of A load
using ThS staining from 2.4% (APP/PS1 + HFD) to
1.27% (APP/PS1 + HFD+EAE) (p < 0.05, Fig. 5 G).
Moreover, IHC quantification for A1–42 peptides
revealed reduction of cortical A load from 23%
(APP/PS1 + HFD) to 18% (APP/PS1 + HFD+EAE)
(p < 0.05, Fig. 6 C).
In addition, GFAP positive cells surround-
ing A plaques were evaluated. A reduction
of size glia surrounding A plaques from
147 m2/cell (APP/PS1 + HFD) to 87 m2/cell
(APP/PS1 + HFD+EAE) (p < 0.05, Fig. 7 G)
was observed. The ratio of GFAP-area/A-
plaque- obtained was 3.6 APP/PS1 + HFD versus
7.0 APP/PS1 + HFD+EAE. However, statistical
differences were not found (p = 0.2380, Fig. 7 H).
In addition, the ratio of IBA1-area/A-diffuse
plaque-area reflects the microglial reaction. The
mean-ratio was reduced from 0.78 (APP/PS1 + HFD)
to 0.29 (APP/PS1 + HFD+EAE) (p < 0.01, Fig. 8 G).
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Fig. 6. Detection of A1–42 peptide in the cortex of APP/PS+HFD transgenic mice untreated and treated with EAE through fluorescent
IHC assay using 12F4 antibody. Images A, a and Aa correspond to the APP/PS1 + HFD experimental group; B, b and Bb correspond to the
APP/PS1 + HFD+EAE. C) A1–42 peptide depositions was evaluated as % of immunoreactive area density. EAE treatment proved effective
in a decrease of % value of A1–42 (∗p < 0.05). Results were presented as mean ± SEM. Statistical analysis was performed through a Student
t-test. Scale bar 100 m.
DISCUSSION
EAE is composed of pentacyclic triterpenoids and
different polyphenol derivatives, which have been
demonstrated to have anti-inflammatory properties.
The quinic acid and HHDP derivatives and similar
polyphenols are a new contribution to the chemical
composition of this plant [24–28].
Regarding the physiopathological conditions of
AD, the polyphenols and triterpenoids found in the
leaves of U. molinae, have indeed proved to be
anti-inflammatory, anti-oxidant, and neuroprotective
[38–42]. Specifically, in the present study, the bene-
ficial effects of EAE on the amelioration of cognitive
performance and improvement of some neuropatho-
logical AD biomarkers in female APP/PS1 mice fed
with HFD have been demonstrated. Furthermore,
previous studies reported higher abnormal A pro-
duction and deposition of amyloid plaques in the
brain of females compared with male mice [32, 33].
Also, learning and memory loss has been described to
be higher in female than males [32] and, the effects of
obesogenic diet cause for an exacerbation of preclin-
ical AD neuropathology. Thus, the positive results
in the evaluation of the effects of EAE, at doses
of 30 mg/kg, evidenced clearly its effectiveness as
a potential new natural strategy to prevent AD [43].
The amelioration of cognitive performance and
AD-related pathological features, such as neu-
roinflammation and A deposition observed in
APP/PS1 + HFD mice treated with EAE, supported
that their chemical content may have therapeutic
properties or preventive potential in a mixed model
of preclinical T2DM and AD [44–48]. Its effects on
microglial cells could explain part of the beneficial
effects. Specifically, the content of EAE extracts in
pentacyclic triterpenoids, such as corosolic, oleano-
lic/ursolic and its other triterpenoids (Table 2) which
have been recognized to have anti-oxidant and anti-
inflammatory properties [24–28, 39]. The identified
phenolic acids, such as gallic acid, tannins, gallotan-
nins (di-and tri-galloyl derivatives), ellagitannins
(hexahydroxydiphenoyl HHDP and hexose deriva-
tives), and for the first time identified, quinic acid
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Fig. 7. Co-localization study of astrocytes surrounding A depositions in the cortex of APP/PS1 + HFD (A, C, E) and APP/PS1 + HFD+EAE
(B, D, F). Quantification of plaque-localized astrocyte size was performed in a 200 m2 field using 8-bit inverted and split channels. A and
B = immunochemistry merged images for GFAP and ThS Staining. C and D = 8-bit image for GFAP and E and G = 8-bit image for A
depositions. Particle quantification was run on ImageJ software. It was observed that treatment with EAE reduces the astrocyte and plaque
size (∗p < 0.05, H, GFAP area (m2)/cell), but the relationship of GFAP against of A surface depositions remains unchanged (H). Results
were represented as a scatter individual quantification values (Graph G) and mean ± SEM of the analysis of n = 3/group. Statistical analysis
was performed with Student t-test. Scale bar = 50 m.
derivatives (Tables 3 and 4) have also proven to be
anti-inflammatory and anti-oxidant in models of neu-
rodegenerative disease [49–51]. Although, the effect
on astrocytic reaction is less patent due to the treat-
ment does not change the area of GFAP covering a
plaque and it seems that only A load is decreased,
our results clearly indicate that EAE has an inhibitory
effect on the microglial cells reaction in the brain of
APP/PS1 mice as general reactivity on the tissue as
related to quantify of soluble or diffuse aggregates
of A1–42 peptides. However, one of the limitations
of our work has been not to evaluate the levels of
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Fig. 8. Co-localization study of microglia surrounding A diffuse or primitive depositions in the cortex of APP/PS1 + HFD (A, C, E) and
APP/PS1 + HFD+EAE (B, D, F). The ratio of microglia reactivity (IBA1-area)/ A diffuse or primitive (A1–42) was calculated. A and
B = Immunochemistry merged images for IBA1 (green channel) and A1–42 (red channel). C and D = 8-bit image for IBA1 and E and G = 8-
bit image for A1–42. It was observed that treatment with EAE reduces the ratio IB A1 1–42 (∗∗p < 0.01, G). Results were represented
mean ± SEM. Statistical analysis was performed with Student t-test. Scale bar = 50 m.
proinflammatory cytokines or enzymes involved in
the inflammatory process such as cyclooxygenase-2
activity.
Moreover, the action of polyphenols has been asso-
ciated with the prevention and treatment of dementia;
supporting the results obtained in our study with the
NORT that demonstrated the improvement in cogni-
tive capabilities in WT+HFD and APP/PS1 + HFD
mice treated with EAE. Other compounds present
in EAE are flavonoids, such as quercetin, myricetin,
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kaempferol, epicatechin/catechin (Tables 3 and 4)
which showed beneficial effects against A neuro-
toxicity [43]. The resulting data is in accordance with
previous reported research that linked chronic treat-
ment with anti-inflammatory drugs and improvement
of AD models [52–55].
Nowadays, the exact etiology of AD is not fully
clear, however, the amyloid hypothesis states that
overproduction of soluble A and aggregations of
this peptide in the brain are primary responsible
causes for the progression of the disease [10–14].
Thus, targeting A reduction mechanisms and its
aggregation is believed to be a possibly suitable strat-
egy to improve the pathology [52–57]. It has been
reported that the main component of diffuse plaques
or pre-plaques are A42 peptides probably the most
pathologic in AD [10–14, 56–68]. In this way, EAE
compounds have shown to modulate A aggregation
[56, 63–68]. Specifically, several phenols as digalloyl
hexose, gallic acid, epicatechin/catechin, quercetin
pentoside and ellagic acid, have been shown to both
modulate amyloid oligomers aggregation and to pro-
tect from the neurotoxic consequences of their release
[64–79]. The reduction of A deposits with EAE
administration supported this hypothesis [64]. On this
point, reduction of microglia reactivity by EAE could
be the result of a decrease in A plaques.
In conclusion, the findings of this study demon-
strate that the chemical composition of EAE has
neuroprotective effects, observed in a mixed model of
preclinical T2DM and AD (APP/PS1 + HFD) model.
Obtained data suggested that improvement in cogni-
tive functions is due to a microglial and astrocytic
reactivity reduction, together with a decrease in A
plaque formation. Also, note that EAE improved
peripheral parameters related to the process of obe-
sity. Considering the reported relationship between
obesity and cognitive loss, the effect of EAE on
metabolism could also contribute to the beneficial
effect of the extract in this preclinical model of AD.
Posterior studies must be conducted to establish the
mechanisms of how the compounds found in the EAE
from U. molinae leaves are able to recover cognition
and pathological parameters of AD, since it would
be a novel potential therapeutic agent to prevent this
neurodegenerative disease.
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Bustamante P, Pérez-Arancibia R, Barriga A, Seguel I,
Garcı́a L, Delporte C (2017) Phenolic composition and
antioxidant capacity of Ugni molinae Turcz. leaves of
different genotypes. Food Chem 215, 219-227.
[26] Delporte C, Backhouse N, Inostroza V, Aguirre MC, Peredo
N, Silva X, Negrete R, Miranda HF (2007) Analgesic activ-
ity of Ugni molinae (murtilla) in mice models of acute pain.
J Ethnopharmacol 112, 162-165.
[27] Rubilar M, Pinelo M, Ihl, M, Scheuermann E, Sineiro J,
Nunez MJ (2006) Murta leaves (Ugni molinae Turcz) as a
source of antioxidant polyphenols. J Agr Food Chem 54,
59-64.
[28] Goity L, Queupil MJ, Jara D, Alegria MSP, Barriga
A, Aguirre MC, Delporte C (2013) An HPLC-UV and
HPLC-ESI MS based method for identification of anti-
inflammatory triterpenoids from the extracts of Ugni moli-
nae. Bol Latinoam Caribe Plantas Med Aromát 12, 108-116.
[29] Zhang S, Chai R, Yang YY, Guo SQ, Wang S, Guo T, Xu SF,
Zhang YH, Wang ZY, Guo C (2017) Chronic diabetic states
worsen Alzheimer neuropathology and cognitive deficits
accompanying disruption of calcium signaling in leptin-
deficient APP/PS1 mice. Oncotarget 8, 43617-43634.
[30] Ruiz HH, Chi T, Shin AC, Lindtner C, Hsieh W, Ehrlich
M, Gandy S, Buettner C (2016) Increased susceptibility to
metabolic dysregulation in a mouse model of Alzheimer’s
disease is associated with impaired hypothalamic insulin
signaling and elevated BCAA levels. Alzheimers Dement
12, 851-861.
[31] Ramos-Rodriguez JJ, Spires-Jones T, Pooler AM, Lechuga-
Sancho AM, Bacskai BJ, Garcia-Alloza M (2017)
Progressive neuronal pathology and synaptic loss induced
by prediabetes and type 2 diabetes in a mouse model of
Alzheimer’s disease. Mol Neurobiol 54, 3428-3438.
[32] Jiao SS, Bu XL, Liu YH, Zhu C, Wang QH, Shen LL,
Liu CH, Wang YR, Yao XQ, Wang YJ (2016) Sex dimor-
phism profile of Alzheimer’s disease-type pathologies in an
APP/PS1 mouse model. Neurotox Res 29, 256-266.
[33] Li X, Feng Y, Wu W, Zhao J, Fu C, Li Y, Ding Y, Wu B,
Gong Y, Yang G, Zhou X (2016) Sex differences between
APPswePS1dE9 mice in A-beta accumulation and pancre-
atic islet function during the development of Alzheimer’s
disease. Lab Anim 50, 275-285.
[34] Ennaceur A, Neave N, Aggleton JP (1997) Spontaneous
object recognition and object location memory in rats: The
effects of lesions in the cingulate cortices, the medial pre-
frontal cortex, the cingulum bundle and the fornix. Exp
Brain Res 113, 509-519.
[35] Michodjehoun-Mestres L1, Amraoui W, Brillouet JM
(2009) Isolation, characterization, and determination of 1-
O-trans-cinnamoyl-beta-D-glucopyranose in the epidermis
and flesh of developing cashew apple (Anacardium occi-
dentale L.) and four of its genotypes. J Agric Food Chem
57, 1377-1382.
[36] Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic
Coordinates, Academic Press, Sydney.
[37] De Lemos L, Junyent F, Camins A, Castro-Torres RD, Folch
J, Olloquequi J, Beas-Zarate C, Verdaguer E, Auladell C
(2018) Neuroprotective effects of the absence of JNK1
or JNK3 isoforms on kainic acid-induced temporal lobe
epilepsy-like symptoms. Mol Neurobiol 55, 4437-4452.
[38] Stohs SJ, Miller H, Kaats GR (2012) A review of the effi-
cacy and safety of banaba (Lagerstroemia speciosa L.) and
corosolic acid. Phyt Res 26, 317-324.
[39] Molino S, Dossena M, Buonocore D, Ferrari F, Venturini L,
Ricevuti G, Verri M (2016) Polyphenols in dementia: From
molecular basis to clinical trials. Life Sci 161, 69-77.
[40] Kajdzanoska M, Petreska J, Stefova M (2011) Comparison
of different extraction solvent mixtures for characterization
of phenolic compounds in strawberries. J Agr Food Chem
59, 5272-5278.
[41] Bhullar KS, Rupasinghe HP (2013) Polyphenols: Multipo-
tent therapeutic agents in neurodegenerative diseases. Oxid
Med Cell Longev 2013, 891748.
[42] Vauzour D (2012) Dietary polyphenols as modulators of
brain functions: Biological actions and molecular mecha-
nisms underpinning their beneficial effects. Oxid Med Cell
Longev 2012, 914273.
[43] McDade E, Bateman RJ (2017) Stop Alzheimer’s before it
starts. Nature 547, 153-155.
1190 D. Jara-Moreno et al. / Ethyl Acetate Extract of Leaves of Ugni molinae Turcz.
[44] Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic
protein: GFAP-thirty-one years (1969-2000). Neurochem
Res 25, 1439-1451.
[45] Pekny M, Wilhelmsson U, Pekna M (2014) The dual role
of astrocyte activation and reactive gliosis. Neurosci Lett
565, 30-38.
[46] Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in
brain aging and Alzheimer’s disease. Biochem Pharmacol
88, 594-604.
[47] Ettcheto M, Petrov D, Pedrós I, Alva N, Carbonell T, Beas-
Zarate C, Pallas M, Auladell C, Folch J, Camins A (2016)
Evaluation of neuropathological effects of a high-fat diet
in a presymptomatic Alzheimer’s disease stage in APP/PS1
mice. J Alzheimers Dis 54, 233-251.
[48] Petrov D, Pedrós I, Artiach G, Sureda FX, Barroso E,
Pallás M, Auladell C, Folch J, Camins A (2015) High-fat
diet-induced deregulation of hippocampal insulin signaling
and mitochondrial homeostasis deficiencies contribute to
Alzheimer disease pathology in rodents. Biochem Biophys
Acta 1852, 1687-1699.
[49] Fragoulis A, Siegl S, Fendt M, Jansen S, Soppa U, Bran-
denburg LO, Wruck CJ (2017) Oral administration of
methysticin improves cognitive deficits in a mouse model
of Alzheimer’s disease. Redox Biol 12, 843-853.
[50] Mani V, Jaafar S M, Azahan NSM, Ramasamy K, Lim
SM, Ming L C, Majeed ABA (2017) Ciproxifan improves
cholinergic transmission, attenuates neuroinflammation and
oxidative stress but does not reduce amyloid level in trans-
genic mice. Life Sci 180, 23-35.
[51] Mori T, Koyama N, Tan J, Segawa T, Maeda M, Town T
(2017) Combination therapy with octyl gallate and ferulic
acid improves cognition and neurodegeneration in a trans-
genic mouse model of Alzheimer disease. J Biol Chem 292,
11310-11325.
[52] McGeer PL, Guo JP, Lee M, Kennedy K, McGeer EG
(2018) Alzheimer’s disease can be spared by nonsteroidal
anti-inflammatory drugs. J Alzheimers Dis 62, 1219-
1222.
[53] Morrison JH, Baxter MG (2012) The ageing cortical
synapse: Hallmarks and implications for cognitive decline.
Nat Rev Neurosci 13, 240-250.
[54] Krause DL, Müller N (2010) Neuroinflammation, microglia
and implications for anti-inflammatory treatment in
Alzheimer’s disease. Int J Alzheimers Dis 2010, 73280.
[55] Becher A, Drenckhahn A, Pahner I, Margittai M, Jahn R,
Ahnert-Hilger G (1999) The synaptophysin-synaptobrevin
complex: A hallmark of synaptic vesicle maturation. J Neu-
rosci 19, 1922-1931.
[56] Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao
J, Li Z (2011) Soluble A levels correlate with cognitive
deficits in the 12-month-old APPswe/PS1dE9 mouse model
of Alzheimer’s disease. Behav Brain Res 222, 342-350.
[57] Jankowsky JL, Zheng H (2017) Practical considerations
for choosing a mouse model of Alzheimer’s disease. Mol
Neurodegener 12, 89.
[58] Ban JY, Nguyen HTT, Lee HJ, Cho SO, Ju HS, Kim
JY, Seong YH (2008) Neuroprotective properties of gallic
acid from Sanguisorbae radix on amyloid beta protein (25-
35)-induced toxicity in cultured rat cortical neurons. Biol
Pharmaceut Bull 31, 149-153.
[59] Choi Y, Kim TD, Paik SR, Jeong K, Jung S (2008) Molec-
ular simulations for anti-amyloidogenic effect of flavonoid
myricetin exerted against Alzheimer’s -amyloid fibrils for-
mation. Bull Korean Chem Soc 29, 1505-1509.
[60] Cuevas E, Limón D, Pérez-Severiano F, Dı́az A, Ortega L,
Zenteno E, Guevara J (2009) Antioxidant effects of epicat-
echin on the hippocampal toxicity caused by amyloid-beta
25-35 in rats. Eur J Pharmacol 616, 122-127.
[61] Murphy MP, LeVine H (2010) Alzheimer’s disease and the
amyloid- peptide. J Alzheimers Dis 19, 311-323.
[62] Re F, Airoldi C, Zona C, Masserini M, Ferla B L, Quat-
trocchi N, Nicotra F (2010) Beta amyloid aggregation
inhibitors: Small molecules as candidate drugs for therapy
of Alzheimer’s disease. Curr Med Chem 17, 2990-3006.
[63] Roher A, Wolfe D, Palutke M, KuKuruga D (1986) Purifi-
cation, ultrastructure, and chemical analysis of Alzheimer
disease amyloid plaque core protein. Proc Nat Acad Sci
U S A 83, 2662-2666.
[64] Torok B, Bag S, Sarkar M, Dasgupta S, Torok M (2013)
Structural features of small molecule amyloid-beta self-
assembly inhibitors. Curr Bioact Com 9, 37-63.
[65] Zhao J, O’Connor T, Vassar R (2011) The contribution
of activated astrocytes to A production: Implications for
Alzheimer’s disease pathogenesis. J Neuroinflammation 8,
150.
[66] Fiori J, Naldi M, Bartolini M, Andrisano V (2012) Dis-
closure of a fundamental clue for the elucidation of the
myricetin mechanism of action as amyloid aggregation
inhibitor by mass spectrometry. Electrophoresis 33, 3380-
3386.
[67] Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H,
Yamada M (2003) Potent anti – amyloidogenic and fibril
– destabilizing effects of polyphenols in vitro: Implications
for the prevention and therapeutics of Alzheimer’s disease.
J Neurochem 87, 172-181.
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